Medications for Lymphangioleiomyomatosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Lymphangioleiomyomatosis.
Found 1 Approved Drug for Lymphangioleiomyomatosis
SIrolimus
Brand Names
Rapamune, Hyftor, Fyarro
SIrolimus
Brand Names
Rapamune, Hyftor, Fyarro
Form: Solution, Injection, Tablet, Gel
Method of administration: Oral, Intravenous, Topical
FDA approval date: July 01, 2001
Classification: mTOR Inhibitor Immunosuppressant
FYARRO ™ is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances